Search is Powered by Google
Cancer / Oncology News

Despite Efforts, Significant Racial Disparities In Cancer Therapy Still Exist

Main Category: Cancer / Oncology
Article Date: 07 Jan 2008 - 13:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Black patients are significantly less likely than their white counterparts to receive therapy for various kinds of cancer, despite recent efforts to close gaps in treatment, according to a study by researchers at Yale School of Medicine published in the January 7 online issue of the journal Cancer.

Prior research revealed racial disparities in cancer care in the early 1990s. Cary P. Gross, M.D., associate professor of medicine at Yale School of Medicine, and colleagues studied the Surveillance, Epidemiology, and End Results (SEER)-Medicare database to evaluate whether greater attention and investment in access to care for all individuals have led to any reduction in cancer treatment disparities. They evaluated patients in the SEER database who had been diagnosed with breast, colorectal, lung or prostate cancer between 1992 and 2002.

After identifying therapies for which racial disparities had been previously reported, the investigators determined whether there had been any changes in care for the overall Medicare population or for white and black patients considered separately. The team evaluated 7,775 colon, 1,745 rectal, 11,207 lung, 40,457 breast and 82,238 prostate cancer cases.

The team found that throughout the study period, black patients were significantly less likely than white patients to receive therapy for cancers of the lung, breast, colon and prostate. For both black and white patients, there were little or no improvements in the proportion of patients receiving therapy for most cancers. There was also no decrease in the magnitude of racial disparities between 1992 and 2002. These racial disparities persisted even after limiting the analysis to patients who had access to a physician prior to their cancer diagnosis.

The findings suggest that there has been little improvement in the overall proportion of Medicare beneficiaries receiving cancer care. They also reveal that racial disparities have not lessened.

"Efforts to mitigate cancer care disparities between 1992 and 2002 appear to have been unsuccessful," said Gross. "Future efforts to reduce cancer disparities should be incorporated into a larger framework that encompasses access to high-quality comprehensive care for all patients with cancer."

Other authors on the study included Elizabeth Wolf and Martin Andersen at Yale and Benjamin D. Smith, M.D., of Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Texas.

Citation: Cancer Vol. 112, No. 4 (Published online January 7, 2008, Print issue date February 15, 2008)

http://www.yale.edu




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
Shocking Pictures To Appear On Cigarette Packets In UK On 1st October
27 Sep 2008
The UK's ten million Smokers may see pictures of rotting teeth, throat cancer, and indications of male impotence (erectile dysfunction) on cigarette packets they buy at the beginning of October...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...